TNYA Tenaya Therapeutics Inc

$TNYA If you’ve been in this stock a while, you will remember this, but it never hurts zooming out for some perspective… On May 15, 2025 we hit an all time low of .36 midday. By Oct 10, 2025 we were at $2.35. That’s more than 6x in less than five months. The catalysts we have on deck this quarter dwarf what happened in that period of time. History may not repeat itself, but it often rhymes.

$TNYA closed $0.5442, up 2.02%, on 3.63M shares, 1.60x average. Recovered 4.43% from the low and finished near the session high. My daily RSI calculation turned up to 28.96. This is the kind of improvement I’ve been watching for: buying that survives the close. Not calling a bottom after one session, but an encouraging change. Still holding my thesis; now watching for follow-through.

$TNYA Strong finish: $0.5871, +7.88%, with 4.19M shares traded, roughly 1.85x average volume. Closed near the high and reclaimed the 5-day and 10-day averages at $0.5551 and $0.5692. Encouraging follow-through. Watching $0.59, then the 20-day near $0.616. Not calling a confirmed reversal, but this is the kind of price-and-volume improvement bulls want to see.

$TNYA why is everyone worried? Stocks go up. Stocks go down. TNYA had good programs/drugs with good results. Once they share those with the world, the stock will go up, right now nothing is being shared, thus stock goes down.

$TNYA You have to drop down to the 4-hour timeframe to find a glimmer of hope; that’s where we see something very interesting, as there is a nice bullish divergence on the RSI. We need to wait for tonight's candle to close, but I have a feeling that if everything goes well, we’ll see a VSA divergence. However, a lot can still happen today, so we need to remain very cautious! As the saying goes, don't count your chickens before they hatch.😅

$TNYA finally said "nah I'm good" to $0.52 and ripped straight up to $0.58 today lmaooo. real volume behind it too (3.64M vs the usual 2.9M), not some ghost-town fake-out wick like we've seen all week. RSI went full overbought mode up at the top (70-80+) before chilling back down to 47. Q4 data + the Nasdaq deadline looming, but I'll take a green candle with real volume over another sad gray flatline any day 🙏 NFA obviously

$TNYA The full catalyst stack between now and the Jan 2027 deadline: 1. MyPEAK-1 interim data (TN-201, hypertrophic cardiomyopathy gene therapy) — Q4 2026 2. RIDGE-1 interim data (TN-401, ARVC gene therapy) — Q4 2026 3. TN-201 regulatory alignment update — status on pivotal trial design discussions with FDA, Q4 2026 4. TN-401 regulatory alignment update — same, Q4 2026 5. TN-301 development plan details — the HDAC6/HFpEF asset, Q4 2026 6. Nov 11 earnings date — likely the vehicle where several of the above get bundled into one event 7. The Nasdaq deadline itself (~late Jan 2027) — not a catalyst for good news, but a forcing event: either the stock is above $1 by then organically, or a reverse split becomes the path to stay listed (Posting this to help push down all the negative useless slop ppl keep posting below)

$TNYA The bottom line it comes down to Science !! It either works or it doesn’t. I think there is no other way around it !! 💹

$TNYA Unfortunately, it was another bearish day yesterday; however, I believe we are reaching a zone where we likely won't drop much further (give or take). The support level we touched yesterday had never been retested before and represents a major support level on the chart. It is always interesting to see that buyers are still present and picking up shares at low prices (accumulation). Let's be patient, friends. (This analysis reflects only my own views, and I encourage you to do your own due diligence 😉.)

$TNYA to anyone newer here. has apparently gone off his rocker because he didn't get his quick pump and dump that he was expecting a month or so ago. He bought toward the top of a spike and has been waiting for it to go back up while we're in a vacuum. He's spouting nonsense and is irrational/illogical. Block him if you don't want to have your board spammed, which he's apparently incessantly doing. I don't have that problem because he blocked me when I pointed it out a few weeks ago :) . He made a claim there are no more warrants, but there are still open warrants, etc. Know what you're investing, why you're investing, and don't get caught up in the emotions of the board especially in something as volatile as a small-cap biotech. I hope you all have a wonderful day, week, month, etc. and I'm looking forward to the Q4 results. I hope their drugs continue to show progress not only because it'll, hopefully, cause the price to rise, but because it could help so many people.

$TNYA Disappointment Is Not the Same as a Broken Thesis: My perspective following the September 23, 2026 AHA lineup release I understand the frustration with TNYA’s momentum. I share the disappointment. Watching a position struggle while waiting for meaningful progress to translate into a stronger stock price is difficult. But the question I keep returning to is not whether I like the price action. It is whether the evidence has changed the reasons I own the company. I anticipated the possibility of a disappointed reaction if the hoped-for AHA inclusion did not materialize. That was an assessment of expectations and risk, not advance knowledge of the outcome. Before this event, I had already established my approach: I would consider revisiting my position if one of six defined triggers fired, rather than rewriting my investment framework in response to a difficult trading day. What changed, and what did not Neither TN-201 nor TN-401 appeared in the published AHA late-breaking lineup when it was checked today, and a search of the broader program did not confirm a MyPEAK-1 or RIDGE-1 readout (AHA late-breaking lineup, AHA program planner). That matters to expectations. I had viewed potential inclusion as an opportunity for visibility and a more concrete catalyst date. That particular opportunity has not been confirmed, and I am not going to replace it with speculation about a surprise announcement. But it is important to distinguish what we hoped for from what the company actually committed to. Tenaya’s stated guidance was for additional interim TN-201 and TN-401 data, along with updates on regulatory discussions, in the fourth quarter of 2026; that guidance did not specify an AHA presentation (Tenaya’s second-quarter business update). The absence of a conference slot does not, by itself, tell me that the treatments stopped working, that a new safety problem emerged, or that the regulatory path deteriorated. Equally, it does not guarantee that the next data will be favorable. It leaves the central investment questions to be answered by evidence. The six conditions that would make me reassess These are my review triggers, not allegations that any of these events has occurred: • Durability failure: Evidence that the benefits of TN-201 or TN-401 are not being maintained, including meaningful deterioration in the clinical or biological measures supporting the treatment thesis. • A materially more difficult FDA pathway: Regulatory requirements that substantially change the expected development plan, such as a required placebo-controlled pivotal study, an expanded trial or additional cohort, or rejection of an accelerated pathway I had been considering as a possibility. • A material safety signal: A serious treatment-related concern, clinical hold, dose-limiting toxicity or other safety development that changes the risk-benefit assessment. • Financing that breaches my predefined limits: An offering or ATM use that crosses the thresholds I established in advance. My framework does not treat all financing as equally good or equally bad; the ownership cost and the time purchased both matter. • Alnylam termination or a material reduction in scope: A change that weakens an important component of the partnership thesis. At the same time, I do not assume that Alnylam owes Tenaya a larger deal or will solve its future funding needs. • A key leadership or scientific departure: An exit involving the people responsible for the company’s strategy, clinical execution or scientific direction. That would require an explanation and a fresh assessment, not an automatic assumption of misconduct. If one of those triggers fires, I revisit the position. “Revisit” means examine the facts and consequences honestly, including whether the original investment case remains credible. It does not mean defend the position regardless of what has changed. Patience still has an economic cost I am not dismissing the share price as irrelevant. In my assessment, a weak price matters because future equity financing could require issuing more shares to raise the same amount of money. Time also matters: a delay can consume cash and reduce negotiating flexibility even before the science itself is disproven. That is why my view is not simply “good science will eventually win.” I need to assess clinical progress, regulatory requirements, funding and the ownership left for existing shareholders together. A company can preserve a valuable program on terms that are disappointing for its shareholders. Nor do I think a positive update automatically guarantees a sustained rally. I want to understand what the data establish, what they leave unresolved, and whether the company has a credible way to fund the next stage. I am investing in that sequence of evidence and execution, not a promise that one headline will fix the chart. Where I stand I am disappointed with the momentum, but I am not revisiting my position solely because this AHA expectation was not met. The distinction matters: disappointment describes how I feel about the outcome; the six triggers describe the evidence that would make me reconsider the investment. My responsibility is to stay consistent without becoming stubborn. That means acknowledging missed expectations, refusing to invent explanations for every trade, and remaining willing to change my mind when the facts warrant it. I do not need every session to validate my decision. I do need the developing evidence to justify continuing to own the company. That is the standard I intend to apply. This is my personal perspective on my own position, not a recommendation for anyone else to buy, sell or hold. Other investors have different liquidity needs, time horizons and tolerances for loss. NFA.

$TNYA In my opinion, we are living through a pivotal moment. Let's wait for the close, but if we finish above $0.6806, we will shift into a very bullish phase.🤞

$TNYA Is this realistic or just a false positive ? Wall Street Analyst Reaffirmations & Price Targets Though institutional volume hasn't exploded yet, Wall Street analysts covering the stock have explicitly reiterated "Buy" ratings: -LifeSci Capital (Cory Jubinville): Reiterated Buy with a $4.00 price target. -Canaccord Genuity (Whitney Ijem): Reiterated Buy with a $5.00 price target, citing pipeline progress and cash runway extension. -H.C. Wainwright (Joseph Pantginis): Reiterated Buy with a $3.00 price target.

$TNYA Guys, there’s really no reason for this much panic. If you don’t believe in the company, the pipeline, or the investment thesis, you can make your own decision and close your position. But creating panic every time the stock pulls back doesn’t help anyone. And we shouldn’t look at this stock in isolation; there’s significant volatility across global markets as well, and we shouldn’t confuse short-term price action with the company’s fundamental story.I’ve made my investment decision very clearly: as long as there is no major deterioration in the clinical development of TN-201 and TN-401, the regulatory process, or the company’s fundamental story, I’m holding my position. A few red days, market volatility, or daily noise won’t change that decision. I’m not focused on the day-to-day chart; I’m focused on the company’s actual progress and long-term potential.Everyone is responsible for their own decisions—if you don’t have confidence, sell; if you believe in the story, stay patient.

$TNYA on its own, missing a specific conference lineup like AHA is not a fundamental issue for $TNYA. It can be frustrating when retail and institutional investors build up anticipation for a "conference catalyst," but program omissions are common in clinical biotechs and usually come down to operational timing rather than problematic trial results.

If $TNYA makes it onto the list after the 23rd, then I feel like there’s absolutely no reason the stock should be declining or flatlining… it signals they have positive data that leaders see fitting to share with the world. It would make no sense for the stock to continue to decline with MORE positive data/news after the 23rd.

$TNYA and right here guys is where you use your second account to buy in big and make them dollars

$TNYA Morning. I believe that with everything going on politically, biotechs most times are heavily effected due to geopolitical macroeconomics!! Money always finds it's way back to solid and promising biotechs! TYNA fits that bill! PATIENCE is all that is required! Don't sit and stare at the screen all day. It will make you go crazy! Then you may end up doing something down the line that you will regret bigtime, after waiting so long! Trust and believe, NO SICKER FEELING IN THE WORLD THAN SELLING OUT OF A LONG HOLD POSITION, AND THEN WATCHING YOUR USE TO BE STOCK SKYROCKET without you! Thats my .02 cents! Blessings all. MBD

$TNYA I've said it before...and I'll say it again. We need a partnership/a financial catalyst that at least somewhat eases the fear of dilution. The market knows the science is good and the company will likely show promising results in the upcoming updates. They just need to prove they can fund themselves in some other way besides dilution (and without capping the company's potential profits in the future). Hopefully the new CFO was specifically brought on to make such a deal happen.

$TNYA Although price is down... I'm actually not mad at what I'm seeing regardingnhow the charts are playing out. Nothing surprising so far. Behaving like any other asset when seeking to sweep liquidity 🤔